{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:07:52Z","timestamp":1789164472550,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virologica Sinica"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.virs.2022.06.002","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T02:20:50Z","timestamp":1654482050000},"page":"731-739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix\u2122 in VZV-primed mice"],"prefix":"10.1016","volume":"37","author":[{"given":"Ning","family":"Luan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virs.2022.06.002_bib1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s13365-017-0519-y","article-title":"Incidence of varicella zoster virus infections of the central nervous system in the elderly: a large tertiary hospital-based series (2007-2014)","volume":"23","author":"Arruti","year":"2017","journal-title":"J.\u00a0Neurovirol."},{"key":"10.1016\/j.virs.2022.06.002_bib2","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMp058091","article-title":"Aging, immunity, and the varicella-zoster virus","volume":"352","author":"Arvin","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.virs.2022.06.002_bib3","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: the SHEZ study","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2022.06.002_bib4","doi-asserted-by":"crossref","first-page":"e1389","DOI":"10.1542\/peds.2012-3303","article-title":"Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study","volume":"131","author":"Baxter","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.virs.2022.06.002_bib5","doi-asserted-by":"crossref","first-page":"9481","DOI":"10.1128\/JVI.00533-06","article-title":"Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection","volume":"80","author":"Berarducci","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2022.06.002_bib6","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/infdis\/jiy279","article-title":"Molecular genetic insights into varicella zoster virus (VZV), the vOka vaccine strain, and the pathogenesis of latency and reactivation","volume":"218","author":"Breuer","year":"2018","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.002_bib7","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.4049\/jimmunol.173.10.6143","article-title":"Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles","volume":"173","author":"Brewer","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.virs.2022.06.002_bib8","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.4049\/jimmunol.161.8.4000","article-title":"Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen","volume":"161","author":"Brewer","year":"1998","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.virs.2022.06.002_bib9","first-page":"310","article-title":"Immunogenicity of varicella-zoster virus glycoprotein E formulated with lipid nanoparticles and","volume":"9","author":"Cao","year":"2021","journal-title":"Nucleic Immunostimulators in Mice. Vaccines (Basel)"},{"key":"10.1016\/j.virs.2022.06.002_bib10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/vaccines9111261","article-title":"An established Th2-oriented response to an alum-adjuvanted SARS-CoV-2 subunit vaccine is not reversible by sequential immunization with nucleic acid-adjuvanted Th1-oriented subunit vaccines","volume":"9","author":"Cao","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.virs.2022.06.002_bib11","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2011.04.081","article-title":"Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines","volume":"29","author":"Carstens","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2022.06.002_bib12","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.002_bib13","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1056\/NEJMe1505050","article-title":"A\u00a0new vaccine to prevent herpes zoster","volume":"372","author":"Cohen","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.virs.2022.06.002_bib14","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 Years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.002_bib15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 Years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.virs.2022.06.002_bib16","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2022.06.002_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0264-410X(96)00228-9","article-title":"Induction of neutralizing antibody and T-cell responses to varicella-zoster virus (VZV) using Ty-virus-like particles carrying fragments of glycoprotein E (gE)","volume":"15","author":"Garcia-Valcarcel","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2022.06.002_bib18","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.virs.2022.06.002_bib19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jiu279","article-title":"Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve","volume":"210","author":"Gilbert","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.002_bib20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/CVI.00310-07","article-title":"A\u00a0double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax","volume":"15","author":"Gilderman","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.virs.2022.06.002_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002367","article-title":"CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection","volume":"7","author":"Haberthur","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virs.2022.06.002_bib22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.7326\/0003-4819-159-11-201312030-00006","article-title":"Examination of links between herpes zoster incidence and childhood varicella vaccination","volume":"159","author":"Hales","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.virs.2022.06.002_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-1702(95)01270-2","article-title":"Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells","volume":"40","author":"Haumont","year":"1996","journal-title":"Virus Res."},{"key":"10.1016\/j.virs.2022.06.002_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108216","article-title":"Immune response of C57BL\/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants","volume":"101","author":"He","year":"2021","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.virs.2022.06.002_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2011.05.019","article-title":"The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production","volume":"154","author":"Henriksen-Lacey","year":"2011","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.virs.2022.06.002_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/003591576505800106","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc. Roy. Soc. Med."},{"key":"10.1016\/j.virs.2022.06.002_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijpharm.2015.10.057","article-title":"Double emulsion solvent evaporation techniques used for drug encapsulation","volume":"496","author":"Iqbal","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.virs.2022.06.002_bib28","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Clinical practice","volume":"371","author":"Johnson","year":"2014","journal-title":"Postherpetic neuralgia. N. Engl. J. Med."},{"key":"10.1016\/j.virs.2022.06.002_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/74715","article-title":"Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children","volume":"6","author":"Krause","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.virs.2022.06.002_bib30","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/infdis\/jiv164","article-title":"Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus","volume":"212","author":"Laing","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.002_bib31","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1080\/21645515.2021.1898917","article-title":"Estimating the basic reproductive number of varicella in South Korea incorporating social contact patterns and seroprevalence","volume":"17","author":"Lee","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virs.2022.06.002_bib32","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A\u00a0phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.002_bib33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/cid\/ciq077","article-title":"Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination","volume":"52","author":"Leung","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.002_bib34","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/14760584.2017.1395703","article-title":"Studies with herpes zoster vaccines in immune compromised patients","volume":"16","author":"Levin","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.virs.2022.06.002_bib35","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.002_bib36","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/21645515.2017.1420446","article-title":"Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model","volume":"14","author":"Liu","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virs.2022.06.002_bib37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijpharm.2018.10.054","article-title":"Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors","volume":"553","author":"Liu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.virs.2022.06.002_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.vaccine.2020.12.005","article-title":"Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8\u2217 nanoparticle rotavirus vaccine","volume":"39","author":"Liu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2022.06.002_bib39","first-page":"309","article-title":"Simian varicella virus pathogenesis","volume":"342","author":"Mahalingam","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.virs.2022.06.002_bib40","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2249.2008.03633.x","article-title":"Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors","volume":"152","author":"Malavige","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.virs.2022.06.002_bib41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/viro.2002.1556","article-title":"The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells","volume":"304","author":"Mo","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.virs.2022.06.002_bib42","doi-asserted-by":"crossref","first-page":"11377","DOI":"10.1128\/JVI.74.23.11377-11387.2000","article-title":"Glycoprotein E of varicella-zoster virus enhances cell-cell contact in polarized epithelial cells","volume":"74","author":"Mo","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2022.06.002_bib43","doi-asserted-by":"crossref","first-page":"12406","DOI":"10.1128\/JVI.78.22.12406-12415.2004","article-title":"Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo","volume":"78","author":"Moffat","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2022.06.002_bib44","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","article-title":"Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","volume":"38","author":"Monslow","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2022.06.002_bib45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.mbs.2008.12.009","article-title":"Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella","volume":"218","author":"Ogunjimi","year":"2009","journal-title":"Math. Biosci."},{"key":"10.1016\/j.virs.2022.06.002_bib46","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A\u00a0vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.virs.2022.06.002_bib47","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/JVI.03445-13","article-title":"Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia","volume":"88","author":"Steain","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2022.06.002_bib48","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0140-6736(74)90144-5","article-title":"Live vaccine used to prevent the spread of varicella in children in hospital","volume":"2","author":"Takahashi","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2022.06.002_bib49","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00425-018-2911-0","article-title":"Recent advances in steroidal saponins biosynthesis and in vitro production","volume":"248","author":"Upadhyay","year":"2018","journal-title":"Planta"},{"key":"10.1016\/j.virs.2022.06.002_bib50","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/vaccines9030222","article-title":"Natural and synthetic saponins as vaccine adjuvants","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.virs.2022.06.002_bib51","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12250-020-00261-y","article-title":"Immune responses to varicella-zoster virus glycoprotein E formulated with poly(lactic-co-glycolic acid) nanoparticles and nucleic acid adjuvants in mice","volume":"36","author":"Wang","year":"2021","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virs.2022.06.002_bib52","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.virs.2022.06.002_bib53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/mpat.1993.1064","article-title":"A\u00a0mouse model for varicella-zoster virus latency","volume":"15","author":"Wroblewska","year":"1993","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.virs.2022.06.002_bib54","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.vaccine.2019.02.048","article-title":"Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice","volume":"37","author":"Wui","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2022.06.002_bib55","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.vaccine.2016.02.007","article-title":"A\u00a0highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice","volume":"34","author":"Zhu","year":"2016","journal-title":"Vaccine"}],"container-title":["Virologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X22001080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X22001080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:18:11Z","timestamp":1761851891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1995820X22001080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1995820X22001080"],"URL":"https:\/\/doi.org\/10.1016\/j.virs.2022.06.002","relation":{},"ISSN":["1995-820X"],"issn-type":[{"value":"1995-820X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix\u2122 in VZV-primed mice","name":"articletitle","label":"Article Title"},{"value":"Virologica Sinica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virs.2022.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}